Capricor Therapeutics' Buy Thesis Ahead Of Deramiocel PDUFA Date

Group 1 - Capricor Therapeutics, Inc. (CAPR) is a biotechnology company focused on two platforms: cardiosphere-derived cell therapy (Deramiocel) and StealthX exosome engineering [1] - Deramiocel is considered the flagship candidate of the company and has received FDA approval [1]